Stockpolly
Search
NAUT · NASDAQ · Biotechnology

Nautilus Biotechnology (NAUT)

Builds the Voyager platform for intact-protein and proteoform analysis.

$0.9212
Pre-market−0.04 (−4.22%)
At close$0.9618(+3.81%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000000000000
Cost of revenue22222600021−1
Gross profit−2−2−2−2−2−6000−2−11
181820191714191715141517
Research & development11121212121112101011910
678763776657
General & administrative000000776600
Other expenses000000000−300
Operating income−19−20−22−21−19−20−19−17−15−15−16−16
333332222211
Interest income333332222211
Other non-operating income−3−3−3−3−3−2000−2−10
Income before tax−16−17−19−18−16−18−17−15−14−14−15−14
Net income from continuing operations−16−17−19−18−16−18−17−15−14−14−15−14
Net income−16−17−19−18−16−18−17−15−14−14−15−14
EPS, basic−$0.13−$0.14−$0.15−$0.14−$0.13−$0.14−$0.13−$0.12−$0.11−$0.11−$0.12−$0.11
EPS, diluted−$0.13−$0.14−$0.15−$0.14−$0.13−$0.14−$0.13−$0.12−$0.11−$0.11−$0.12−$0.11
Weighted average shares, basic125125125125125126126126126126127127
Weighted average shares, diluted125125125125125126126126126126127127
EBITDA−14−15−17−16−15−11−17−15−14−12−13−16
Depreciation & amortization222226222210
EBIT−16−17−19−18−16−18−19−17−15−14−15−16